Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

The researchers obtained data from 601 randomized controlled trials. They found that treatment with SGLT2 inhibitors, GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP-4) inhibitors lowered ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease (CKD), according to Spherix Global Insights.

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...